<p>Tivic Health Systems, Inc. ((TIVC)) 已召开其第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
<p>尽管面临净亏损增加和生产延迟等挑战，Tivic Health Systems, Inc. 在其战略转型和 Entolimod 的开发方面取得了显著进展。财报电话会议期间的整体情绪乐观，突显了公司的进步和改善的财务状况。</p>
<h2>战略转型</h2>
<p>Tivic Health 成功地将其重点从生物电子学扩展到生物制药，特别是针对与免疫系统相关的治疗。这一战略转变标志着公司的一次重大转型，使其在生物制药这一前景广阔的领域中占据了有利位置。</p>
<h2>Entolimod 开发进展</h2>
<p>公司在 Entolimod 的开发方面取得了进展，转移了两个新药研究申请 (INDs) 并完成了细胞系验证。这些步骤对于 Tivic 在将 Entolimod 作为军事对策和储备药物的制造准备方面至关重要。</p>
<h2>财务状况</h2>
<p>Tivic Health 的财务状况得到加强，现金及现金等价物从 200 万美元上升至 350 万美元，公司保持无债务的资产负债表。这一改善为未来的增长提供了坚实的基础。</p>
<h2>毛利率改善</h2>
<p>公司报告称毛利率有所改善，排除库存准备金后，毛利率从去年的 35% 增加至 42%。这表明成本管理和运营效率有所提升。</p>
<h2>净亏损增加</h2>
<p>尽管有积极的发展，Tivic Health 在 2025 年第三季度的净亏损增加至 260 万美元，而 2024 年第三季度为 140 万美元。这一净亏损的增加反映了公司在其战略转型中的持续投资。</p>
<h2>生产延迟</h2>
<p>由于合同制造商面临的财务压力，Tivic 的生产计划遭遇延迟。这些延迟对公司的生产时间表构成挑战。</p>
<h2>销售成本增加</h2>
<p>销售成本显著上升至 291,000 美元，较 82,000 美元大幅增加，主要由于库存准备金。这一增加影响了公司的整体盈利能力。</p>
<h2>九个月收入下降</h2>
<p>九个月期间的收入从 2024 年的 600,000 美元下降至 302,000 美元，归因于单位销售减少。这一下降突显了在维持销售势头方面面临的挑战。</p>
<h2>前瞻性指导</h2>
<p>展望未来，Tivic Health 致力于向生物制药市场的战略转型，重点关注 Entolimod 作为急性辐射综合症 (ARS) 的军事对策。公司在与 ARS 和晚期癌症相关的 IND 转移方面取得了进展。尽管九个月收入有所下降，Tivic 对未来持乐观态度，得益于毛利率的改善和现金储备的增加。</p>
<p>总之，Tivic Health Systems, Inc. 正在经历一个转型阶段，专注于生物制药和 Entolimod 的开发。尽管公司面临净亏损增加和生产延迟等挑战，但其改善的财务状况和战略重点为未来提供了良好的前景。</p>

TIVC

<p>Tivic Health Systems, Inc. 举行了第三季度财报电话会议，强调其从生物电子学向生物制药的战略转变，专注于免疫系统治疗。尽管面临净亏损增加和制造延迟等挑战，公司改善了财务状况，现金储备上升至 350 万美元，资产负债表无债务。毛利率提高至 42%，尽管净亏损增加至 260 万美元。Tivic 对未来持乐观态度，专注于 Entolimod 的开发作为军事对策，尽管九个月的收入有所下降</p>

<p>Tivic Health Systems, Inc. ((TIVC)) has held its Q3 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Tivic Health Systems, Inc. ((TIVC)) 已召开其第三季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的 <em>ETF</em> AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 的见解。</li>
</ul>
</div><p>Tivic Health Systems, Inc. has shown notable progress in its strategic transformation and development of Entolimod, despite facing challenges such as increased net loss and manufacturing delays. The overall sentiment during the earnings call was optimistic, highlighting the company’s advancements and improved financial position.</p>
<div class="lb-trans"><p>尽管面临净亏损增加和生产延迟等挑战，Tivic Health Systems, Inc. 在其战略转型和 Entolimod 的开发方面取得了显著进展。财报电话会议期间的整体情绪乐观，突显了公司的进步和改善的财务状况。</p>
</div><h2>Strategic Transformation</h2>
<div class="lb-trans"><h2>战略转型</h2>
</div><p>Tivic Health has successfully expanded its focus from bioelectronics to biologic pharmaceuticals, particularly targeting treatments related to the immune system. This strategic shift marks a significant transformation for the company, positioning it in the promising field of biologic pharmaceuticals.</p>
<div class="lb-trans"><p>Tivic Health 成功地将其重点从生物电子学扩展到生物制药，特别是针对与免疫系统相关的治疗。这一战略转变标志着公司的一次重大转型，使其在生物制药这一前景广阔的领域中占据了有利位置。</p>
</div><h2>Entolimod Development Progress</h2>
<div class="lb-trans"><h2>Entolimod 开发进展</h2>
</div><p>The company has made strides in the development of Entolimod by transferring two Investigational New Drug applications (INDs) and completing cell line verification. These steps are crucial as Tivic advances manufacturing readiness for Entolimod as a military countermeasure and stockpile drug.</p>
<div class="lb-trans"><p>公司在 Entolimod 的开发方面取得了进展，转移了两个新药研究申请 (INDs) 并完成了细胞系验证。这些步骤对于 Tivic 在将 Entolimod 作为军事对策和储备药物的制造准备方面至关重要。</p>
</div><h2>Financial Position</h2>
<div class="lb-trans"><h2>财务状况</h2>
</div><p>Tivic Health’s financial position has strengthened, with cash and cash equivalents rising to $3.5 million from $2 million, and the company maintaining a debt-free balance sheet. This improvement provides a solid foundation for future growth.</p>
<div class="lb-trans"><p>Tivic Health 的财务状况得到加强，现金及现金等价物从 200 万美元上升至 350 万美元，公司保持无债务的资产负债表。这一改善为未来的增长提供了坚实的基础。</p>
</div><h2>Gross Margin Improvement</h2>
<div class="lb-trans"><h2>毛利率改善</h2>
</div><p>The company reported an improvement in gross margins, excluding inventory reserves, which increased to 42% from 35% compared to the previous year. This indicates better cost management and efficiency in operations.</p>
<div class="lb-trans"><p>公司报告称毛利率有所改善，排除库存准备金后，毛利率从去年的 35% 增加至 42%。这表明成本管理和运营效率有所提升。</p>
</div><h2>Increased Net Loss</h2>
<div class="lb-trans"><h2>净亏损增加</h2>
</div><p>Despite positive developments, Tivic Health experienced an increased net loss of $2.6 million for Q3 2025, compared to $1.4 million in Q3 2024. This rise in net loss reflects the company’s ongoing investments in its strategic transformation.</p>
<div class="lb-trans"><p>尽管有积极的发展，Tivic Health 在 2025 年第三季度的净亏损增加至 260 万美元，而 2024 年第三季度为 140 万美元。这一净亏损的增加反映了公司在其战略转型中的持续投资。</p>
</div><h2>Manufacturing Delays</h2>
<div class="lb-trans"><h2>生产延迟</h2>
</div><p>Tivic faced delays in its manufacturing schedule due to financial stress experienced by its contract manufacturer. These delays pose challenges to the company’s production timelines.</p>
<div class="lb-trans"><p>由于合同制造商面临的财务压力，Tivic 的生产计划遭遇延迟。这些延迟对公司的生产时间表构成挑战。</p>
</div><h2>Cost of Sales Increase</h2>
<div class="lb-trans"><h2>销售成本增加</h2>
</div><p>The cost of sales rose significantly to $291,000 from $82,000, primarily due to inventory reserves. This increase impacts the company’s overall profitability.</p>
<div class="lb-trans"><p>销售成本显著上升至 291,000 美元，较 82,000 美元大幅增加，主要由于库存准备金。这一增加影响了公司的整体盈利能力。</p>
</div><h2>Decreased Nine-Month Revenue</h2>
<div class="lb-trans"><h2>九个月收入下降</h2>
</div><p>Revenue for the nine-month period decreased to $302,000 from $600,000 in 2024, attributed to reduced unit sales. This decline highlights the challenges faced in maintaining sales momentum.</p>
<div class="lb-trans"><p>九个月期间的收入从 2024 年的 600,000 美元下降至 302,000 美元，归因于单位销售减少。这一下降突显了在维持销售势头方面面临的挑战。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, Tivic Health is committed to its strategic transformation towards the biopharmaceutical market, with a focus on Entolimod as a military countermeasure for acute radiation syndrome (ARS). The company has made progress in transferring INDs related to ARS and advanced cancer. Despite a decrease in nine-month revenue, Tivic is optimistic about its future, supported by improved gross margins and increased cash reserves.</p>
<div class="lb-trans"><p>展望未来，Tivic Health 致力于向生物制药市场的战略转型，重点关注 Entolimod 作为急性辐射综合症 (ARS) 的军事对策。公司在与 ARS 和晚期癌症相关的 IND 转移方面取得了进展。尽管九个月收入有所下降，Tivic 对未来持乐观态度，得益于毛利率的改善和现金储备的增加。</p>
</div><p>In conclusion, Tivic Health Systems, Inc. is navigating a transformative phase with a focus on biologic pharmaceuticals and the development of Entolimod. While the company faces challenges such as increased net loss and manufacturing delays, its improved financial position and strategic focus offer a promising outlook for the future.</p>
<div class="lb-trans"><p>总之，Tivic Health Systems, Inc. 正在经历一个转型阶段，专注于生物制药和 Entolimod 的开发。尽管公司面临净亏损增加和生产延迟等挑战，但其改善的财务状况和战略重点为未来提供了良好的前景。</p>
</div>

Tivic Health 的财报电话会议：战略调整与面临的挑战